ARTICLE | Clinical News
Histalean: Phase II started
September 15, 2008 7:00 AM UTC
Obecure began the double-blind, placebo-controlled, European Phase II (BET-207) trial to evaluate 48 or 96 mg/day Histalean for 12 weeks in 180 obese, premenopausal women. ...